CJC-1295 (DAC)

Name: CJC-1295 (DAC)
SKU: 7190
Availability: InStock

Brands PeptideLion

$39.00 – $56.00

Sku:

N/A

Brands: PeptideLion

Description

Overview

What is CJC-1295?

CJC-1295 is a synthetic GHRH (growth hormone releasing hormone) analogue made up of 30 amino acids. It has been found to be highly effective with regards to the increase of growth hormone secretion and IGF-1 without negatively affecting the pulsatility of GH secretion.

CJC-1295 is often combined with Ipamorelin due to its enhanced specificity as a GHRH. This peptide generates similar increases in growth hormone secretion, but without the appetite stimulation and increase in cortisol, acetylcholine, prolactin, and aldosterone seen with other peptides in its class. This peptide has been found to be very well-tolerated and perfect when combined with Ipamorelin.

CJC-1295 was further modified by adding DAC (Drug Affinity Complex) to it. DAC binds to a blood protein called albumin, which increases its half-life to 8 days. It is called CJC 1295 + DAC. CJC 1295 can also be compounded in a non-DAC form which mimics a more normal physiologic GH spike each night.

The longer half-life from the DAC binding to albumin means injections are only required once or twice per week. However, the long half-life and relatively constant blood level provide a constant stimulus for GH release from the pituitary through the GHRH receptor, which is not physiological. This can decrease the GH pulse amplitude which will result in decreased GH tissue stimulation.

Is CJC-1295 DAC same as CJC-1295?

CJC-1295 DAC and CJC-1295 (Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical, but the difference between the two peptides is the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life of up to approximately 8 days. Many scientists have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered much more natural as they produce a short pulse of Human Growth Hormone.

Scientific Information

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. Placebo-treated GHRHKO mice and mice heterozygous for the GHRHKO allele served as controls. GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length. Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization. Femur and tibia length remained normal in animals treated every 24 and 48 h. Relative lean mass and subcutaneous fat mass were normal in all treated groups. CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images. These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.

How CJC-1295 Works In The Body

CJC 1295 offers many benefits to the body, including:

Increased growth hormone secretion and IGF-1 Levels with no increase in prolactin
Increased Body Weight and Length through increased protein synthesis
Increased Muscle Growth
Increased Bone Density
Improved Immune Function
Improved Cognition and Memory
Increased Collagen Production
Increased Fat Loss
Increased Cellular Repair and Regeneration

CJC-1295 also promotes slow wave deep sleep, which is responsible for the highest level of muscle growth and memory retention and rejuvenation.

Research Highlights

CJC-1295 DAC is a long-acting growth hormone-releasing hormone, which causes the anterior pituitary gland to release more growth hormone. DAC is an additive moiety that prolongs the plasma half-life of CJC-1295. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies show that combining a GHRP-6 with CJC-1295 DAC significantly increases the release of GH and IGF-1 production without an increase in prolactin. CJC-1295 DAC is an exceptionally designed peptide known for being the finest hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin, protecting the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bound to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

Despite the fact that there has been plenty of research on CJC-1295 + DAC in relation to how it functions and the benefits that can be derived from such functionality, it should be emphasized that the peptide is still just intended for scientific study at this point in time. Because of this, any findings or observations relating to CJC-1295 + DAC’s overall functionality, mechanics, benefits, should exclusively be the product of study performed in a strictly contained environment.